CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookfield Business Partners

New Oriental Education & Technology Group

Everi

Weightwatchers International Inc.

U.S. service sector and job market are flourishing, per January's ISM's non-manufacturing report. Investors can make the most by investing in the top-performing sectors.

US Service Sector Accelerates in January: 5 Stocks to Buy

CareDx’s transplant specific algorithms enable personalized care CareDx’s transplant specific algorithms enable personalized care

CareDx Launches AiTraC Conference

Calavo Growers

Darling Ingredients

KalVista Pharma

Simply Good Foods

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

5 Defensive Stocks to Counter Coronavirus Scare

Cirrus Logic

Great Lakes Dredge & Dock

Installed Building Products

LPL Financial Hlds

Markets have done well in years when AFL teams have won the Super Bowl than in years when the victors are from the NFL. With the Kansas City Chiefs winning this year, we can expect stocks to climb.

Super Bowl Results Show Stock Gains in February: 5 Picks

CE mark approval enables global availability of dd-cfDNA measurement for monitoring transplant health CE mark approval enables global availability of dd-cfDNA measurement for monitoring transplant health

CareDx’s AlloSeq cfDNA Awarded CE Mark Approval

SOUTH SAN FRANCISCO, Calif., Jan.  08, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that on December 20, 2019, Magistrate Judge Christopher Burke issued a report recommending that the U.S. District Court for the District of Delaware reject Natera Inc.’s motion to dismiss CareDx’s false advertising complaint.

CareDx's False Advertising Complaint Upheld By Court

Congress introduces a bill to extend Medicare coverage of immunosuppressive medications for kidney transplant recipients Congress introduces a bill to extend Medicare coverage of immunosuppressive medications for kidney transplant recipients

CareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients

Alibaba

HealthEquity

EchoStar

Tempur Sealy International

For the first time in many years, many active managers are outperforming index funds in 2019, and that should be a loud wake-up call to passive investors.

5 New Raymond James Analysts Favorite Stock Picks With Massive Upside Potential

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Boston Scientific

Gilead Sciences

For the first time in years, for 2019 active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential

CareDx drives continued transplant focused improvements to AlloSure CareDx drives continued transplant focused improvements to AlloSure

CareDx Advances Patient Care with AlloSure 3.0

Despite the company's stellar third quarter, the market focused on soft fourth-quarter guidance.

Here's Why CareDx Stock Is Sinking Today

CareDx (CDNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About CareDx (CDNA) Rating Upgrade to Strong Buy

CareDx's (CDNA) CEO Peter Maag on Q3 2019 Results - Earnings Call Transcript

CareDx joins UI Health and NKF to meet with Senator Durbin and advocate for action on anti-rejection drug coverage for kidney transplant patients CareDx joins UI Health and NKF to meet with Senator Durbin and advocate for action on anti-rejection drug coverage for kidney transplant patients

CareDx Participates in Transplant Roundtable with Senator Durbin

As of late, it has definitely been a great time to be an investor in CareDx, Inc (CDNA).

CareDx, Inc (CDNA) Shares March Higher, Can It Continue?

CareDx protects transplantation innovation by enforcing patent protection CareDx protects transplantation innovation by enforcing patent protection

CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor

CareDx partners with NanoString to improve precision of transplant biopsies CareDx partners with NanoString to improve precision of transplant biopsies

CareDx Adds HistoMap To Testing Portfolio

Artificial Intelligence algorithm predicts long-term kidney transplant outcomes Artificial Intelligence algorithm predicts long-term kidney transplant outcomes

CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication

AlloSeq Tx 17 is a best in class HLA typing solution with the most comprehensive sequencing and easiest workflow AlloSeq Tx 17 is a best in class HLA typing solution with the most comprehensive sequencing and easiest workflow

CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting

BRISBANE, Calif., Sept.  17, 2019  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in the Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2nd at 2:25 PM ET. 

CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference

CareDx will establish access to dd-cfDNA surveillance solutions for transplant patients worldwide CareDx will establish access to dd-cfDNA surveillance solutions for transplant patients worldwide

CareDx launches AlloSeq® cfDNA at ESOT 2019

Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools

CareDx Acquires XynManagement

Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio

Chris Cournoyer Joins CareDx Board of Directors

CareDx expands leadership with cfDNA for transplant care CareDx expands leadership with cfDNA for transplant care

AlloSure for Heart Transplant Patients Receives CMS Draft Coverage

CareDx partnership with American Association of Kidney Patients yields key patient insights CareDx partnership with American Association of Kidney Patients yields key patient insights

News for CareDx Stock (CDNA)